Traumatic Brain Injury – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Traumatic Brain Injury – Pipeline Review, H2 2017’, provides an overview of the Traumatic Brain Injury pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Traumatic Brain Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Traumatic Brain Injury and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Traumatic Brain Injury

The report reviews pipeline therapeutics for Traumatic Brain Injury by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Traumatic Brain Injury therapeutics and enlists all their major and minor projects

The report assesses Traumatic Brain Injury therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Traumatic Brain Injury

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Traumatic Brain Injury

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Traumatic Brain Injury pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

ALSP Inc

Apollo Endosurgery Inc

Aptinyx Inc

Athersys Inc

Beech Tree Labs Inc

Biogen Inc

Cantex Pharmaceuticals Inc

Cognosci Inc

Eustralis Pharmaceuticals Ltd

Intellect Neurosciences Inc

International Stem Cell Corp

Ischemix Inc

JT Pharmaceuticals Inc

Karyopharm Therapeutics Inc

Kyorin Pharmaceutical Co Ltd

Levolta Pharmaceuticals Inc

Lixte Biotechnology Holdings Inc

MandalMed Inc

Mapreg SAS

Neuralstem Inc

Neuren Pharmaceuticals Ltd

Neurofx Inc

NeuroNascent Inc

NeuroVive Pharmaceutical AB

New World Laboratories Inc

NoNO Inc

NuvOx Pharma LLC

Omeros Corp

Oxeia Biopharmaceuticals Inc

Prevacus Inc

QR Pharma Inc

RegeneRx Biopharmaceuticals Inc

Rubicon Biotechnology Inc

Sage Therapeutics Inc

SanBio Inc

STATegics Inc

Stemedica Cell Technologies Inc

SynZyme Technologies LLC

Tetra Discovery Partners LLC

vasopharm GmbH

VG Life Sciences Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Traumatic Brain Injury - Overview 6

Traumatic Brain Injury - Therapeutics Development 7

Traumatic Brain Injury - Therapeutics Assessment 19

Traumatic Brain Injury - Companies Involved in Therapeutics Development 31

Traumatic Brain Injury - Drug Profiles 52

Traumatic Brain Injury - Dormant Projects 227

Traumatic Brain Injury - Discontinued Products 230

Traumatic Brain Injury - Product Development Milestones 231

Appendix 242

List of Tables

List of Tables

Number of Products under Development for Traumatic Brain Injury, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Traumatic Brain Injury – Pipeline by ALSP Inc, H2 2017

Traumatic Brain Injury – Pipeline by Apollo Endosurgery Inc, H2 2017

Traumatic Brain Injury – Pipeline by Aptinyx Inc, H2 2017

Traumatic Brain Injury – Pipeline by Athersys Inc, H2 2017

Traumatic Brain Injury – Pipeline by Beech Tree Labs Inc, H2 2017

Traumatic Brain Injury – Pipeline by Biogen Inc, H2 2017

Traumatic Brain Injury – Pipeline by Cantex Pharmaceuticals Inc, H2 2017

Traumatic Brain Injury – Pipeline by Cognosci Inc, H2 2017

Traumatic Brain Injury – Pipeline by Eustralis Pharmaceuticals Ltd, H2 2017

Traumatic Brain Injury – Pipeline by Intellect Neurosciences Inc, H2 2017

Traumatic Brain Injury – Pipeline by International Stem Cell Corp, H2 2017

Traumatic Brain Injury – Pipeline by Ischemix Inc, H2 2017

Traumatic Brain Injury – Pipeline by JT Pharmaceuticals Inc, H2 2017

Traumatic Brain Injury – Pipeline by Karyopharm Therapeutics Inc, H2 2017

Traumatic Brain Injury – Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2017

Traumatic Brain Injury – Pipeline by Levolta Pharmaceuticals Inc, H2 2017

Traumatic Brain Injury – Pipeline by Lixte Biotechnology Holdings Inc, H2 2017

Traumatic Brain Injury – Pipeline by MandalMed Inc, H2 2017

Traumatic Brain Injury – Pipeline by Mapreg SAS, H2 2017

Traumatic Brain Injury – Pipeline by Neuralstem Inc, H2 2017

Traumatic Brain Injury – Pipeline by Neuren Pharmaceuticals Ltd, H2 2017

Traumatic Brain Injury – Pipeline by Neurofx Inc, H2 2017

Traumatic Brain Injury – Pipeline by NeuroNascent Inc, H2 2017

Traumatic Brain Injury – Pipeline by NeuroVive Pharmaceutical AB, H2 2017

Traumatic Brain Injury – Pipeline by New World Laboratories Inc, H2 2017

Traumatic Brain Injury – Pipeline by NoNO Inc, H2 2017

Traumatic Brain Injury – Pipeline by NuvOx Pharma LLC, H2 2017

Traumatic Brain Injury – Pipeline by Omeros Corp, H2 2017

Traumatic Brain Injury – Pipeline by Oxeia Biopharmaceuticals Inc, H2 2017

Traumatic Brain Injury – Pipeline by Prevacus Inc, H2 2017

Traumatic Brain Injury – Pipeline by QR Pharma Inc, H2 2017

Traumatic Brain Injury – Pipeline by RegeneRx Biopharmaceuticals Inc, H2 2017

Traumatic Brain Injury – Pipeline by Rubicon Biotechnology Inc, H2 2017

Traumatic Brain Injury – Pipeline by Sage Therapeutics Inc, H2 2017

Traumatic Brain Injury – Pipeline by SanBio Inc, H2 2017

Traumatic Brain Injury – Pipeline by STATegics Inc, H2 2017

Traumatic Brain Injury – Pipeline by Stemedica Cell Technologies Inc, H2 2017

Traumatic Brain Injury – Pipeline by SynZyme Technologies LLC, H2 2017

Traumatic Brain Injury – Pipeline by Tetra Discovery Partners LLC, H2 2017

Traumatic Brain Injury – Pipeline by vasopharm GmbH, H2 2017

Traumatic Brain Injury – Pipeline by VG Life Sciences Inc, H2 2017

Traumatic Brain Injury – Dormant Projects, H2 2017

Traumatic Brain Injury – Dormant Projects, H2 2017 (Contd..1), H2 2017

Traumatic Brain Injury – Dormant Projects, H2 2017 (Contd..2), H2 2017

Traumatic Brain Injury – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Traumatic Brain Injury, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Top 10 Routes of Administration, H2 2017

Number of Products by Stage and Top 10 Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports